WO2002083127A1 - Compositions inhibant la modification proteique - Google Patents

Compositions inhibant la modification proteique Download PDF

Info

Publication number
WO2002083127A1
WO2002083127A1 PCT/JP2002/003345 JP0203345W WO02083127A1 WO 2002083127 A1 WO2002083127 A1 WO 2002083127A1 JP 0203345 W JP0203345 W JP 0203345W WO 02083127 A1 WO02083127 A1 WO 02083127A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein modification
inhibitory compositions
compounds
tetrazole group
inhibitory
Prior art date
Application number
PCT/JP2002/003345
Other languages
English (en)
Japanese (ja)
Inventor
Toshio Miyata
Original Assignee
Tokai University Educational System
Kurokawa, Kiyoshi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokai University Educational System, Kurokawa, Kiyoshi filed Critical Tokai University Educational System
Priority to JP2002580931A priority Critical patent/JPWO2002083127A1/ja
Publication of WO2002083127A1 publication Critical patent/WO2002083127A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des compositions inhibant la modification protéique, qui contiennent comme ingrédient actif des composés, présentant un groupe tétrazole, ou des sels pharmacologiquement acceptables desdits composés. Des composés présentant un groupe tétrazole, tels que des bloqueurs du récepteurs de l'angiotensine, conviennent à l'inhibition d'une modification protéique avec des composés carbonylés, provoquée par une hyperglyclémie ou un stress oxydatif. Ces inhibiteurs de modification protéique ne présentent aucun effet secondaire tel qu'une carence en vitamine B6.
PCT/JP2002/003345 2001-04-09 2002-04-03 Compositions inhibant la modification proteique WO2002083127A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002580931A JPWO2002083127A1 (ja) 2001-04-09 2002-04-03 蛋白修飾物生成抑制組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001147115 2001-04-09
JP2001-147115 2001-04-09

Publications (1)

Publication Number Publication Date
WO2002083127A1 true WO2002083127A1 (fr) 2002-10-24

Family

ID=18992647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/003345 WO2002083127A1 (fr) 2001-04-09 2002-04-03 Compositions inhibant la modification proteique

Country Status (2)

Country Link
JP (1) JPWO2002083127A1 (fr)
WO (1) WO2002083127A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018649A1 (fr) * 2003-08-25 2005-03-03 Nagoya Industrial Science Research Institute Agent permettant d'inhiber la formation d'un produit final de saccharification
WO2005030737A1 (fr) * 2003-09-30 2005-04-07 Sankyo Company, Limited Derive phenylene comportant un cycle tetrazole ou un cycle thiazolidinedione
WO2005051930A1 (fr) * 2003-11-27 2005-06-09 Tokai University Educational System Inhibiteur de formation de proteines modifiees
WO2006028007A1 (fr) * 2004-09-06 2006-03-16 Kowa Co., Ltd. Medicament contre les maladies glomerulaires
WO2007026962A1 (fr) * 2005-08-31 2007-03-08 Daiichi Sankyo Company, Limited Dérivé de phénylène
JPWO2005054205A1 (ja) * 2003-12-05 2007-06-28 学校法人東海大学 蛋白修飾物生成抑制剤
US7417052B2 (en) 2004-09-29 2008-08-26 Sankyo Company, Limited Phenylene derivative having tetrazole ring or thiazolidinedione ring

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252753A (en) * 1991-11-01 1993-10-12 Ortho Pharmaceutical Corporation Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof
WO1999063930A2 (fr) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Nouveaux modulateurs des récepteurs de l'angiotensine et leurs utilisations
WO2000038676A1 (fr) * 1998-12-23 2000-07-06 Novartis Ag Utilisation d'un antagoniste du recepteur d'at-1 ou d'un modulateur du recepteur d'at-2 pour traiter des affections associees a une augmentation des recepteurs d'at-1 ou d'at-2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252753A (en) * 1991-11-01 1993-10-12 Ortho Pharmaceutical Corporation Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof
WO1999063930A2 (fr) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Nouveaux modulateurs des récepteurs de l'angiotensine et leurs utilisations
WO2000038676A1 (fr) * 1998-12-23 2000-07-06 Novartis Ag Utilisation d'un antagoniste du recepteur d'at-1 ou d'un modulateur du recepteur d'at-2 pour traiter des affections associees a une augmentation des recepteurs d'at-1 ou d'at-2

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018649A1 (fr) * 2003-08-25 2005-03-03 Nagoya Industrial Science Research Institute Agent permettant d'inhiber la formation d'un produit final de saccharification
WO2005030737A1 (fr) * 2003-09-30 2005-04-07 Sankyo Company, Limited Derive phenylene comportant un cycle tetrazole ou un cycle thiazolidinedione
WO2005051930A1 (fr) * 2003-11-27 2005-06-09 Tokai University Educational System Inhibiteur de formation de proteines modifiees
JPWO2005054205A1 (ja) * 2003-12-05 2007-06-28 学校法人東海大学 蛋白修飾物生成抑制剤
JP4837992B2 (ja) * 2003-12-05 2011-12-14 学校法人東海大学 蛋白修飾物生成抑制剤
WO2006028007A1 (fr) * 2004-09-06 2006-03-16 Kowa Co., Ltd. Medicament contre les maladies glomerulaires
JPWO2006028007A1 (ja) * 2004-09-06 2008-05-08 興和株式会社 糸球体疾患治療剤
US7417052B2 (en) 2004-09-29 2008-08-26 Sankyo Company, Limited Phenylene derivative having tetrazole ring or thiazolidinedione ring
WO2007026962A1 (fr) * 2005-08-31 2007-03-08 Daiichi Sankyo Company, Limited Dérivé de phénylène

Also Published As

Publication number Publication date
JPWO2002083127A1 (ja) 2004-09-30

Similar Documents

Publication Publication Date Title
EG25251A (en) Synergistic fungicidal compositions.
WO2008081399A3 (fr) Dérivés 2-aza-bicyclo[3.1.0]hexane
HK1067863A1 (en) Compositions for potentiating glutathione
WO2006068826A3 (fr) Inhibiteurs de la kinase erbb a base de 2-pyrimidinyle pyrazolopyridine
ZA200305993B (en) Herbicidal compositions.
HK1048271A1 (en) Pharmaceutical composition for inhibiting retinoidskin damage.
WO2008006528A3 (fr) Nouvelles compositions pharmaceutiques comprenant du lévétiracétam
WO2005077932A3 (fr) Antagonistes du recepteur de la chimiokine
WO2007067506A3 (fr) Inhibiteurs d'erbb kinase de 2-pyrimidinyl-pyrazolopyridine
EP1900362A3 (fr) Dérivés alpha-aminoamides utiles dans le traitement des troubles d'accoutumance
WO2008048963A3 (fr) Compositions naturelles pour tuer des parasites sur un animal de compagnie
ZA200408670B (en) Trizole derivatives as tachykinin receptor antagonists.
AU2003255845A1 (en) Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ZA200702960B (en) Fungicidal active ingredient combinations containing fluoxastrobin
WO2009016560A3 (fr) Dérivés de trans-3-aza-bicyclo[3.1.0]hexane
AP2005003195A0 (en) Herbicidal compositions.
IL190067A0 (en) Pharmaceutical compositions containing an active vitamin d compound for gastrointestinal disorders
WO2007003264A3 (fr) Derives d'acide polyaspartique dans des produits de revetement contenant du polysiloxane
EP2308320A3 (fr) Amidon hydroxypropylique pour la prévention/traitement du diabète
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
MXPA03006991A (es) Derivados de piperidina como antagonistas de neurocinina 1.
WO2007087026A3 (fr) Forme solide de amg 706 et compositions pharmaceutiques contenant ledit composé
WO2002083127A1 (fr) Compositions inhibant la modification proteique
TW200733963A (en) Cough inhibitor
ZA200501387B (en) Antimicrobial compositions.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002580931

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase